$7.2B GW Pharma acquisition is another sign of cannabis normalization

By Alex Halperin
Feb 4, 2021
This week Jazz Pharmaceuticals said it would acquire GW Pharmaceuticals in a $7.2B cash and stock deal, the strongest indication yet of big drugmakers’ long-speculated interest in cannabis. In 2018, the U.S. Food and Drug Administration (FDA) approved GW’s Epidiolex, a...

This content is FREE for registered users.

To view this content you need to register as a Weedweek member.

If you are already a member please login below.